» Toleranzia's CEO: "Several large companies are following us"
» WntResearch provides update ahead of TO6 release
» Dicot doses first phase I participants
» Annexin CEO: “By far our biggest success in a long time”
» Toleranzia's CEO on development and issuance
Read BioStock's weekly newsletter for v.35 here.
See the BioStock Investor Pitch with Toleranzia and CEO Charlotte Fribert via the banner below.
Morning news
FDA grants Cantargia Orphan Drug Designation for CAN10 for the treatment of systemic sclerosis. Read more.
Corline Biomedical announces that a 12-month follow-up of Renaparin supports safety and indicates positive treatment effect. Read more.
Subscription price for the exercise of warrants series TO 6 in WntResearch has been set at SEK 0,14 per share and the exercise period begins today, September 6. Read more.
Vicore Pharma informs about presentations at European Respiratory Society (ERS) International Congress 2023. Read more.
Devyser Diagnostics and Thermo Fisher Scientific expands collaboration for NGS products in post-transplant follow-up by adding Brazil. Read more.
RLS Global announces that the first patient has been included in a new clinical study on pressure ulcers. Read more.
Arne Hauge has been appointed as the new CFO of Bio-Works. Read more.
AstraZeneca updates on FDA's regulatory review of Ultomiris for the treatment of the rare disease NMOSD. Read more.
Nightingale Health provides blood sample analysis services for a large American healthcare system. Read more.
Mendus will participate in HC Wainwright's 25th Annual Global Investment Conference in September. Read more.
Although Faron Pharmaceuticals will participate in the HC Wainwright conference. Read more.
CS Medica updates regarding its collaboration with RongShi after participating in two industry events in China. Read more.
EXACT Therapeutics and Cordance Medical announces strategic partnership to revolutionize drug delivery to the brain. Read more.
Gubra submits an application for clinical trial in the UK. Read more.
Stayble Therapeutics terminates the liquidity guarantee agreement. Read more.
Reports
Insider trading
Communiqués
News since Tuesday lunch
Camurus announced the launch of Brixadi in the United States for the treatment of opioid addiction. Read more.
Diamyd Medical announced that the pivotal phase III study in type 1 diabetes with Diamyd is expanding to the United States. Read more.
Orexo will participate in Pareto Securities 14th Annual Healthcare Conference 2023. Read more.
ExpreS2ion Biotechnologies published a video presentation. Read more.
Alvotech announced management changes. Read more.
The subscription price for Tendonitis warrants of series TO 1 were set at SEK 1,20 per share. Read more.
Arcede Pharma announced that a recording of the company's investor presentation on September 5 is available. Read more.
This morning's price development
Winner: Moberg Pharma + 20,25%, Miris Holding +10,33%, Lipidor +7,09%, Lipum +6,83%, Stayble Therapeutics +6,49%
Förlorare: Eurocine Vaccines -53,85%, PharmaLundensis -29,09%, Annexin Pharmaceuticals -11,98%, WntResearch -10,65%, Chosa Oncology -10,22%
Index: OMSX30 2185 -0,83%, Healthcare -1,48%
More from BioStock
» Aptahem's CEO comments on Q2 and looks ahead
» BrainCool comments on the increased order intake
» Stayble includes first patient in herniated disc study
» Arcede Pharma aims for clinic with issue
» CombiGene's new CEO talks about his visions for the company